Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

43

Revenue 2017

Perjeta

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Perjeta was produced by Roche.

Roche posts minor sales miss in Q4 as biosimilar pressure grows

Roche posts minor sales miss in Q4 as biosimilar pressure grows Schwan highlighted four of these newer Roche medicines as driving the sales growth, namely  Perjeta (pertuzumab) for HER2-positive breast cancer,   Ocrevus (ocrelizumab) for multiple sclerosis, haemophilia therapy  Hemlibra (emicizumab) and

AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu

AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine). ... This first regulatory approval is based on the DESTINY-Breast01 trial in patients who had previously been treated with Herceptin, Perjeta or Kadcyla.

EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla

EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla HER2 antibodies, lagging behind Herceptin and Perjeta (pertuzumab).

AZ, Daiichi Sankyo strengthen case for HER2 candidate

AZ, Daiichi Sankyo strengthen case for HER2 candidate Kadcyla is the smallest in terms of sales in Roche’s HER2 franchise, with its sales falling behind those of Herceptin (trastuzumab) and Perjeta (pertuzumab). ... lines of treatment, to become a direct challenger to Roche’s Herceptin/Perjeta

Mylan, Biocon’s Herceptin biosimilar launched in US

Mylan, Biocon’s Herceptin biosimilar launched in US To counteract the onslaught from these biosimilars, Roche has  prepped filings for a fixed-dose combination of both Herceptin and its other antibody blockbuster Perjeta (pertuzumab), promising simpler dosing of the ... minutes. Currently, Herceptin and

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...
OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...

Infographics